David Matthew Friedman
CIK: 0002108980
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Friedman David Matthew
Friedman David Matthew (SEC CIK 0002108980) files insider reports with the SEC as Director of Benitec Biopharma Inc. (BNTC), Director of Avalyn Pharma Inc. (AVLN) and Director of Veradermics, Inc (MANE).
Signal8 holds 5 ownership filings by Friedman David Matthew (3 Form 3, 2 Form 4), filed between Feb 3, 2026 and May 28, 2026. Those filings report 2 transactions, from Feb 3, 2026 to May 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Friedman David Matthew's filings is in NEW HAVEN, CT.
Recent filings by Friedman David Matthew
Other insiders filing for Benitec Biopharma Inc. (BNTC)
- Mates Sharon, Director
- MONTANOVA CAPITAL, LLC, Director
- Mehta Kishan, Director
- Smith Edward F, Director
- Francis Peter, Director
- BUCHI J KEVIN, Director